A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Public ClinicalTrials.gov record NCT04195750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
Study identification
- NCT ID
- NCT04195750
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 755 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2020 (Actual)
- Primary completion
- Apr 15, 2024 (Actual)
- Completion
- Oct 14, 2026 (Estimated)
- Last update posted
- Oct 20, 2026
2020 – 2026
United States locations
- U.S. sites
- 29
- U.S. states
- 22
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Faculty Office Towers 1132 ( Site 1538) | Birmingham | Alabama | 35294 | — |
| University of California San Diego Moores Cancer Center ( Site 1546) | La Jolla | California | 92093-0698 | — |
| St. Joseph Heritage Healthcare Local Lab ( Site 1531) | Santa Rosa | California | 95403 | — |
| University of Colorado Cancer Center ( Site 1540) | Aurora | Colorado | 80045 | — |
| UCHealth Highlands Ranch Hospital ( Site 1560) | Highlands Ranch | Colorado | 80129 | — |
| Sibley Memorial Hospital ( Site 1559) | Washington D.C. | District of Columbia | 20016 | — |
| Northwest Georgia Oncology Centers PC ( Site 1520) | Marietta | Georgia | 30060 | — |
| The University of Chicago Medical Center ( Site 1539) | Chicago | Illinois | 60637 | — |
| Ochsner Medical Center ( Site 1522) | New Orleans | Louisiana | 70121-2429 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514) | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital ( Site 1558) | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center ( Site 1501) | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute ( Site 1505) | Boston | Massachusetts | 02215 | — |
| Henry Ford Cancer Center ( Site 1511) | Detroit | Michigan | 48202 | — |
| Hattiesburg Clinic ( Site 1509) | Hattiesburg | Mississippi | 39401 | — |
| St. Vincent Frontier Cancer Center ( Site 1549) | Billings | Montana | 59102 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 1513) | Hackensack | New Jersey | 07601 | — |
| University of Rochester Medical Center ( Site 1543) | Rochester | New York | 14642 | — |
| University of North Carolina at Chapel Hill ( Site 1537) | Chapel Hill | North Carolina | 27514 | — |
| Oncology Hematology Care, Inc. ( Site 1524) | Cincinnati | Ohio | 45242 | — |
| Cleveland Clinic Main ( Site 1504) | Cleveland | Ohio | 44195 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523) | Tulsa | Oklahoma | 74146 | — |
| Oregon Health & Science University ( Site 1553) | Portland | Oregon | 97239 | — |
| Abramson Cancer Center ( Site 1525) | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center ( Site 1506) | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina ( Site 1518) | Charleston | South Carolina | 29425 | — |
| Henry Joyce Cancer Clinic ( Site 1544) | Nashville | Tennessee | 37232 | — |
| Texas Oncology-Austin Central ( Site 1533) | Austin | Texas | 78731 | — |
| Texas Oncology, P.A.-Dallas ( Site 1534) | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 143 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04195750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04195750 live on ClinicalTrials.gov.